Microbix Biosystems Inc. (Microbix) is a Canada-based biotechnology company. Microbix is engaged in research and development, and commercialization of biological products and technologies. It commercializes technologies for influenza vaccine manufacturing. The Company�s development pipeline includes Virus Yield Enhancement Technology (VIRUSMAX), LumiSort (Semen Sexing Technology) and a thrombolytic drug, Kinlytic (Urokinase). Microbix has developed two tissue versions of the Urokinase drug, which includes ThromboClear and CathClear. VIRUSMAX is engaged in the production of influenza vaccine. Microbix�s Virology products business is used by multinational customers in the diagnostic industry to manufacture their finished products based on the cell culture and virology. It sells approximately 40 products to over 100 companies in the United States, Europe and Asia. In February 2013, the Company sold its Water-for-Injection business to Irvine Scientific in California.